Form 8-K - Current report:
SEC Accession No. 0001625101-22-000014
Filing Date
2022-03-31
Accepted
2022-03-31 16:19:35
Documents
13
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plse-20220331x8k.htm   iXBRL 8-K 82408
2 EX-99.1 plse-20220331xex99_1.htm EX-99.1 495855
  Complete submission text file 0001625101-22-000014.txt   721568

Data Files

Seq Description Document Type Size
3 EX-101.SCH plse-20220331.xsd EX-101.SCH 2771
4 EX-101.LAB plse-20220331_lab.xml EX-101.LAB 14660
5 EX-101.PRE plse-20220331_pre.xml EX-101.PRE 10501
7 EXTRACTED XBRL INSTANCE DOCUMENT plse-20220331x8k_htm.xml XML 4631
Mailing Address 3957 POINT EDEN WAY HAYWARD CA 94545
Business Address 3957 POINT EDEN WAY HAYWARD CA 94545 510-906-4600
Pulse Biosciences, Inc. (Filer) CIK: 0001625101 (see all company filings)

EIN.: 465696597 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37744 | Film No.: 22792840
SIC: 3841 Surgical & Medical Instruments & Apparatus